✦ LIBER ✦

Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis

✍ Scribed by Denis Wakefield; Angela Jennings; Peter J McCluskey

Book ID: 114431710
Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 120 KB
Volume: 28
Category: Article
ISSN: 1442-6404
DOI: 10.1046/j.1442-9071.2000.00282.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immune parameters associated with early

Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis

✍ Hui-Yun Wang; Makoto Matsui; Shin-ichi Araya; Nobuyuki Onai; Kouji Matsushima; T 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Characterisation of uveitis in associati

Characterisation of uveitis in association with multiple sclerosis

✍ Messenger, Wyatt (author);Hildebrandt, Lena (author);Mackensen, Friederike (auth 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 583 KB

Characterisation of uveitis in associati

Characterisation of uveitis in association with multiple sclerosis

✍ Messenger, Wyatt (author);Hildebrandt, Lena (author);Mackensen, Friederike (auth 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 583 KB

The effect of oral and intravenous methy

The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis

✍ B Sharrack; R.A.C Hughes; R.W Morris; S Soudain; O Wade-Jones; D Barnes; P Brown 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Long-term effects of intravenous high do

Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis

✍ M. Zorzon; R. Zivadinov; L. Locatelli; D. Giuntini; M. Toncic; A. Bosco; D. Nasu 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

Immune deviation following pulse cycloph

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

✍ Derek R. Smith; Konstantin E. Balashov; David A. Hafler; Samia J. Khoury; Dr. Ho 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 794 KB

Multiple sclerosis (MS) is postulated to be a Thl-type cell-mediated autoimmune disease. Thus therapies that decrease T cell interferon (1FN)-y production or increase interleukin (1L)-4 production would be expected to have an ameliorating effect on MS. Some progressive MS patients receiving pulse cy